| 1 | IMP will be labeled as ''PF-04236921 106mg/vial, Clonal SC lyophilized form''. | - | - | - | - | [1] 96 96 |
| 2 | IMP will be labeled as PF-04236921 106mg/vial, Clonal SC lyophilized form | - | - | - | - | [1] 96 96 |
| 3 | PF-04236921 | - | - | - | - | [2] 49 49, 96 |
| 4 | PF-04236921 SC injection | - | - | - | - | [1] 96 96 |
| 5 | The investigational medicinal product (IMP) may be labelled as either PF-04236921 106 mg/vial, Clonal SC lyophilized form” or PF-04236921 Powder for Injection, 106 mg/vial”. Supplies labelled with either nomenclature are equivalent. | - | - | - | - | [1] 96 96 |
| 6 | The investigational medicinal product (IMP) will be labeled as PF-04236921 106 mg/vial, Clonal SC lyophilized form, which is equivalent to PF-04236921 Powder for Injection, 106 mg/vial as described in the enclosed CTA | - | - | - | - | [1] 96 96 |
| 7 | The investigational medicinal product (IMP) will be labeled as PF-04236921 106 mg/vial, Clonal SC lyophilized form, which is equivalent to PF-04236921 Powder for Injection, 106 mg/vial as described in the enclosed CTA. | - | - | - | - | [1] 96 96 |